FDA Approves Second Drug Treatment for Polyneuropathy – APhA submits compounding comments to FDA.

2507_GraphicImage_062315-piAlabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves Second Drug Treatment for Polyneuropathy – APhA submits compounding comments to FDA. – (866) 348-2889.

The FDA has approved inotersen (Tegsedi, Akcea Therapeutics), an antisense oligonucleotide (ASO) that inhibits the production of the transthyretin (TTR) protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.1,2 This is the second FDA approved drug for hATTR, following patisiran (Onpattro), which was approved August 10.1

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.